Literature DB >> 19830442

Functional changes following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Chengguo Zuo1, Feng Wen, Jiaqing Li, Yan Liu, Shixian Long, Shizhou Huang, Meng Li.   

Abstract

PURPOSE: To assess the functional changes of retina in patients affected by polypoidal choroidal vasculopathy (PCV) after combined intravitreal bevacizumab and photodynamic therapy (PDT) by means of contrast sensitivity (CS) test and color vision test.
METHODS: Twelve eyes of 12 patients were included in the study. The CS and color vision were measured and compared before the combined treatment and 1, 3 and 6 months after the treatment.
RESULTS: The patients had an improvement in CS over pre-treatment values at the all of the five spatial frequencies. And the differences at 1.5 cycle per degree (cpd) at 1 and 3 months after treatment (p = 0.04 and 0.007 respectively) were statistically significant. The mean square root of total error score for color vision of the FM 100-hue test decreased after treatment and the change was significant at 3 and 6 months after treatment (p < 0.001 and 0.011 respectively).
CONCLUSIONS: Combined intravitreal bevacizumab and PDT can improve the CS at low spatial frequency and color vision in patients affected by PCV, although the significant increases of CS were no longer found at 6-month follow-up.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19830442     DOI: 10.1007/s00417-009-1210-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  28 in total

1.  Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy.

Authors:  M Mauget-Faÿsse; M Quaranta-El Maftouhi; E De La Marnièrre; A Leys
Journal:  Eur J Ophthalmol       Date:  2006 Sep-Oct       Impact factor: 2.597

2.  Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Yumiko Kurashige; Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2008-07-09       Impact factor: 5.258

3.  Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Peter Stalmans; Claus Eckardt; Matthias Lüke; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Am J Ophthalmol       Date:  2006-07       Impact factor: 5.258

4.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

5.  Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes.

Authors:  Olcay Tatar; Edwin Kaiserling; Annemarie Adam; Faik Gelisken; Kei Shinoda; Michael Völker; Bart A Lafaut; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Arch Ophthalmol       Date:  2006-06

6.  Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration.

Authors:  Ingrid U Scott; William J Feuer; Julie A Jacko
Journal:  Am J Ophthalmol       Date:  2002-03       Impact factor: 5.258

7.  Contrast acuity in cataracts of different morphology and association to self-reported visual function.

Authors:  Eva Stifter; Stefan Sacu; Arnulf Thaler; Herbert Weghaupt
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-12       Impact factor: 4.799

8.  Idiopathic polypoidal choroidal vasculopathy of the macula.

Authors:  R S Moorthy; A T Lyon; M F Rabb; R F Spaide; L A Yannuzzi; L M Jampol
Journal:  Ophthalmology       Date:  1998-08       Impact factor: 12.079

9.  Spatial contrast sensitivity in macular disorder.

Authors:  S Mitra
Journal:  Doc Ophthalmol       Date:  1985-04-30       Impact factor: 2.379

10.  Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity.

Authors:  N Bansback; C Czoski-Murray; J Carlton; G Lewis; L Hughes; M Espallargues; C Brand; J Brazier
Journal:  Qual Life Res       Date:  2006-11-22       Impact factor: 4.147

View more
  1 in total

Review 1.  Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases.

Authors:  In Hwan Hong; Sung Pyo Park
Journal:  Indian J Ophthalmol       Date:  2017-07       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.